London School of Economics and Political Science: Accelerated Cancer Drug Approvals Deliver Limited Survival Gains at High Cost
December 17, 2025
December 17, 2025
LONDON, England, Dec. 17 (TNSjou) -- The University of London - London School of Economics and Political Science issued the following news release:
* * *
Accelerated cancer drug approvals deliver limited survival gains at high cost
Early access to new cancer drugs, granted accelerated approval by the U.S. Food and Drug Administration (FDA), has provided mixed benefits for patients while costing Medicare billions of dollars, reveals new research published in . . .
* * *
Accelerated cancer drug approvals deliver limited survival gains at high cost
Early access to new cancer drugs, granted accelerated approval by the U.S. Food and Drug Administration (FDA), has provided mixed benefits for patients while costing Medicare billions of dollars, reveals new research published in . . .